Are ACE inhibitors acceptable ingredients in polypills?

Affiliations

¹ Department of Cardiology, Mount Sinai Hospital, New York, NY 10029, USA; Department of Cardiology and Clinical Research, University of Bern, Bern, Switzerland; Department of Internal Medicine and Gerontology, Jagiellonian University Kraków, Kraków, Poland. Electronic address: messerli.f@gmail.com.
² The Leon H Charney Division of Cardiology, New York University School of Medicine, New York, NY, USA.
³ Department of Cardiology and Clinical Research, University of Bern, Bern, Switzerland.
⁴ Department of Internal Medicine and Gerontology, Jagiellonian University Kraków, Kraków, Poland.
⁵ Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, Lausanne, Switzerland.

Comment

Franz H Messerli et al. Lancet. 2017.

. 2017 Jul 1;390(10089):26.

doi: 10.1016/S0140-6736(17)31468-X.

¹ Department of Cardiology, Mount Sinai Hospital, New York, NY 10029, USA; Department of Cardiology and Clinical Research, University of Bern, Bern, Switzerland; Department of Internal Medicine and Gerontology, Jagiellonian University Kraków, Kraków, Poland. Electronic address: messerli.f@gmail.com.
² The Leon H Charney Division of Cardiology, New York University School of Medicine, New York, NY, USA.
³ Department of Cardiology and Clinical Research, University of Bern, Bern, Switzerland.
⁴ Department of Internal Medicine and Gerontology, Jagiellonian University Kraków, Kraków, Poland.
⁵ Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, Lausanne, Switzerland.

No abstract available

Comment on

Polypills: an essential medicine for cardiovascular disease.
The Lancet. The Lancet. Lancet. 2017 Mar 11;389(10073):984. doi: 10.1016/S0140-6736(17)30695-5. Lancet. 2017. PMID: 28290999 No abstract available.